Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $47.00.

Several analysts have commented on the company. Bank of America lifted their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Wolfe Research began coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler boosted their target price on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a report on Friday, March 20th. Finally, Guggenheim started coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price target for the company.

Tyra Biosciences Stock Down 0.8%

Shares of TYRA stock traded down $0.26 during mid-day trading on Friday, hitting $32.75. 998,700 shares of the company’s stock were exchanged, compared to its average volume of 936,203. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -15.02 and a beta of 0.76. Tyra Biosciences has a fifty-two week low of $9.96 and a fifty-two week high of $40.65. The stock has a 50-day simple moving average of $31.32 and a two-hundred day simple moving average of $32.16.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, analysts anticipate that Tyra Biosciences will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new position in shares of Tyra Biosciences in the 1st quarter worth $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $51,000. Chung Wu Investment Group LLC purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after acquiring an additional 534 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after acquiring an additional 1,668 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.